LNP Characterization and Analytical Development Summit on November 18-20, 2025 in Boston, United States

LNPs continue to dominate as the non-viral delivery vehicle of choice given their ability to encapsulate fragile payloads, such as mRNA, siRNA, gRNA and more, and deliver them into target cells with high efficacy. However, critical challenges remain in assessing targeted LNP surface functionalization, evaluating encapsulation efficiency for multivalent formulations, and aligning analytical results with process performance.

The 3rd LNP Characterization and Analytical Development Summit is the only global event dedicated to this specialized field, providing analytical experts with in-depth technical insights into accelerating development timelines, overcoming analytical gaps and streamlining regulatory submissions for fast-tracking approval of high-quality LNP drug products.

Join experts from Pfizer, Novo Nordisk, Prime Medicine, Tessera Therapeutics, GSK, Sanofi, and more as we explore the cutting edge of LNP characterization and analytics. Don’t miss this opportunity to collaborate with the brightest minds shaping the future of LNP drug development.

URLs:

Tickets: https://go.evvnt.com/3169531-2?pid=10008

Brochure: https://go.evvnt.com/3169531-3?pid=10008

Time: 7:30 AM - 4:30 PM

Prices:

Conference Only - Drug Developer: USD 2999.00,

Conference Only - Solution Provider: USD 3699.00,

Conference Only - Academics: USD 2599.00,

Conference + Workshop Day - Drug Developer: USD 4197.00,

Conference + Workshop Day - Solution Provider: USD 5097.00,

Conference + Workshop Day - Academics: USD 3597.00

Speakers: Jean-Luc Fraikin, Chief Executive Officer, Spectradyne LLC, Kan Zhu, Director, Head of Analytical Biochemistry, CSL, Mohit Gupta, Principal Scientist, Tessera Therapeutics, Justin Fang, Senior Scientist, RNA NewCo, Elias Halabi, Senior Scientist II, Novo Nordisk, Wei-Chiang Chen, Associate Director, Sanofi, Zack Zhang, Director - Analytical Development, Beam Therapeutics Inc., Dandan Ling, Director, Formulation Research and Development, Suzhou Aibo Biotechnology Co., Ltd., Pushkar Saralkar, Senior Scientist, Pfizer, Ruchi Shah, Director, Drug Product, Vaccines Technical Research and Development, GSK US, Ramsey Majzoub, Director, Intellia Therapeutics, Sanjib Saha, Senior Scientist, AstraZeneca, John Haserick, Director, Analytical Research and Development, GlaxoSmithKline, Navid Bizmark, Materials Characterization Team Lead - Senior Principal Scientist, Pfizer, Jeffrey Clogston, Principal Scientist and Head of Physicochemical Characterization Section, National Cancer Institute, Shashank Shukla, Senior Scientist II, Abbvie, Baixue (Dorothy) Xiao, Postdoctoral Fellow, Genentech, Kala Dasuri, CMC, Sanofi, Minjia Wang, Scientist II, Analytical Development, Prime Medicine, Qook Lee, Research Advisor, Eli Lilly and Co., Stephan Stern, Director, Research and Development, Nanotechnology Characterization Lab, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Sam Lai, Professor, Division of Pharmacoengineering and Molecular Pharmaceutics, University of North Carolina - Chapel Hill, Tong (Jenny) Liu, Senior Principal Scientist, United States Pharmacopeia, Kanika Suri, Scientist, Takeda Pharmaceutical, Jikang Wu, Senior Principal Scientist, Regeneron Pharmaceuticals